Search

Your search keyword '"Sukhin, Vladyslav"' showing total 30 results
Start Over Author "Sukhin, Vladyslav"
30 results on '"Sukhin, Vladyslav"'

1. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial

Author

Lorusso, Domenica, Xiang, Yang, Hasegawa, Kosei, Scambia, Giovanni, Leiva, Manuel, Ramos-Elias, Pier, Acevedo, Alejandro, Sukhin, Vladyslav, Cloven, Noelle, Pereira de Santana Gomes, Andrea J, Contreras Mejía, Fernando, Reiss, Ari, Ayhan, Ali, Lee, Jung-Yun, Saevets, Valeriya, Zagouri, Flora, Gilbert, Lucy, Sehouli, Jalid, Tharavichitkul, Ekkasit, Lindemann, Kristina, Lazzari, Roberta, Chang, Chih-Long, Lampé, Rudolf, Zhu, Hong, Oaknin, Ana, Christiaens, Melissa, Polterauer, Stephan, Usami, Tomoka, Li, Kan, Yamada, Karin, Toker, Sarper, Keefe, Stephen M, Pignata, Sandro, and Duska, Linda R

Published
2024
Full Text
View/download PDF

2. SUCCOR morbidity: complications in minimally invasive versus open radical hysterectomy in early cervical cancer

Author

Vázquez-Vicente, Daniel, Boria, Felix, Castellanos, Teresa, Gutierrez, Monica, Chacon, Enrique, Manzour, Nabil, Minguez, Jose Angel, Martin-Calvo, Nerea, Alcazar, Juan Luis, Chiva, Luis, Zanagnolo, Vanna, Querleu, Denis, Arévalo-Serrano, Juan, Căpîlna, Mihai Emil, Fagotti, Anna, Kucukmetin, Ali, Mom, Constantijne, Chakalova, Galina, Aliyev, Shamistan, Malzoni, Mario, Narducci, Fabrice, Arencibia, Octavio, Raspagliesi, Francesco, Toptas, Tayfun, Cibula, David, Kaidarova, Dilyara, Meydanli, Mehmet Mutlu, Tavares, Mariana, Golub, Dmytro, Perrone, Anna Myriam, Poka, Robert, Tsolakidis, Dimitrios, Vujić, Goran, Jedryka, Marcin A, Zusterzeel, Petra L M, Beltman, Jogchum Jan, Goffin, Frederic, Haidopoulos, Dimitrios, Haller, Herman, Jach, Robert, Yezhova, Iryna, Berlev, Igor, Bernardino, Margarida, Bharathan, Rasiah, Lanner, Maximilian, Maenpaa, Minna M, Sukhin, Vladyslav, Feron, Jean-Guillaume, Fruscio, Robert, Kukk, Kersti, Ponce, Jordi, Abdalla, Nabil, Akbayir, Özgür, Akgöl, Sedat, Aksahin, Elif, Alonso-Espias, Maria, Aluloski, Igor, Andrade, Claudia, Badzakov, Nikola, Barrachina, Rosa, Bogani, Giorgio, Bonci, Eduard-Aexandru, Bonsang-Kitzis, Hélène, Brucker, Cosima, Cárdenas, Laura, Casajuana, Andrea, Cavalle, Pere, Cea, Jorge, Chiofalo, Benito, Cordeiro, Gloria, Coronado, Pluvio, Cuadra, Maria, Díez, Javier, Costa, Teresa Diniz da, Domingo, Santiago, Dostalek, Lukas, Demirkiran, Fuat, Erasun, Diego, Fehr, Mathias, Fernandez-Gonzalez, Sergi, Ferrero, Annamaria, Fidalgo, Soledad, Fiol, Gabriel, Galaal, Khadra, García, José, Gebauer, Gerhard, Ghezzi, Fabio, Gilabert, Juan, Gomes, Nana, Gonçalves, Elisabete, Gonzalez, Virginia, Grandjean, Frederic, Guijarro, Miriam, Guyon, Frédéric, Haesen, Jolien, Hernandez-Cortes, Gines, Herrero, Sofía, Pete, Imre, Kalogiannidis, Ioannis, Karaman, Erbil, Kavallaris, Andreas, Klasa, Lukasz, Kotsopoulos, Ioannis, Kovachev, Stefan, Leht, Meelis, Lekuona, Arantxa, Luyckx, Mathieu, Mallmann, Michael, Mancebo, Gemma, Mandic, Aljosa, Marina, Tiermes, Martin, Victor, Martín-Salamanca, María Belén, Martinez, Alejandra, Meili, Gesine, Mendinhos, Gustavo, Mereu, Liliana, Mitrovic, Milena, Morales, Sara, Moratalla, Enrique, Morillas, Bibiana, Myriokefalitaki, Eva, PakižImre, Maja, Petousis, Stamatios, Pirtea, Laurentiu, Povolotskaya, Natalia, Prader, Sonia, Quesada, Alfonso, Redecha, Mikuláš, Roldan, Fernando, Rolland, Philip, Saaron, Reeli, Sarac, Cosmin-Paul, Scharf, Jens-Peter, Smrkolj, Špela, Sousa, Rita, Stepanyan, Artem, Študent, Vladimír, Tauste, Carmen, Trum, Hans, Turan, Taner, Undurraga, Manuela, Uppin, Arno, Vázquez, Alicia, Vergote, Ignace, Vorgias, George, Zapardiel, Ignacio, and Campillo, Francisco

Published
2024
Full Text
View/download PDF

3. Prognostic factors in patients with uterine sarcoma: the SARCUT study

Author

Zapardiel, Ignacio, Gracia Segovia, Myriam, Macuks, Ronalds, Mancari, Rosanna, Achimas-Cadariu, Patriciu, Corrado, Giacomo, Bartusevicius, Arnoldas, Sukhin, Vladyslav, Muruzabal, Juan C, Coronado Martín, Pluvio J, Gardella, Barbara, Piek, Jurgen M, Concin, Nicole, Arab, Clemente, Papatheodorou, Dimitrios, Polterauer, Stephan, Iacoponi, Sara, Nieto, Teresa, Lopez-Sanclemente, Martha C, Trukhan, Hanna, Gil, Maria M, Bakinovskaya, Irina, Dalamanava, Alena, Cucurull, Marc, Rovski, Dzmitry, Baquedano, Laura, Chiva, Luis, Mardas, Marcin, Mavrichev, Siarhei Anatolievich, Klat, Jaroslav, Lopez de la Manzanara, Carlos A, and Yildirim, Yusuf

Published
2023
Full Text
View/download PDF

4. SUCCOR cone study: conization before radical hysterectomy

Author

Chacon, Enrique, Manzour, Nabil, Zanagnolo, Vanna, Querleu, Denis, Núñez-Córdoba, Jorge M, Martin-Calvo, Nerea, Căpîlna, Mihai Emil, Fagotti, Anna, Kucukmetin, Ali, Mom, Constantijne, Chakalova, Galina, Shamistan, Aliyev, Gil Moreno, Antonio, Malzoni, Mario, Narducci, Fabrice, Arencibia, Octavio, Raspagliesi, Francesco, Toptas, Tayfun, Cibula, David, Kaidarova, Dilyara, Meydanli, Mehmet Mutlu, Tavares, Mariana, Golub, Dmytro, Perrone, Anna Myriam, Poka, Robert, Tsolakidis, Dimitrios, Vujić, Goran, Jedryka, Marcin A, Zusterzeel, Petra L M, Beltman, Jogchum Jan, Goffin, Frederic, Haidopoulos, Dimitrios, Haller, Herman, Jach, Robert, Yezhova, Iryna, Berlev, Igor, Bernardino, Margarida, Bharathan, Rasiah, Lanner, Maximilian, Maenpaa, Minna M, Sukhin, Vladyslav, Feron, Jean-Guillaume, Fruscio, Robert, Kukk, Kersti, Ponce, Jordi, Minguez, Jose Angel, Vázquez-Vicente, Daniel, Castellanos, Teresa, Boria, Felix, Alcazar, Juan Luis, Chiva, Luis, Abdalla, Nabil, Akgöl, Sedat, Aksahin, Demirkiran, Aliyev, Shamistan, Alonso-Espias, Maria, Aluloski, Igor, Andrade, Claudia, Badzakov, Nikola, Barrachina, Rosa, Bogani, Giorgio, Bonci, Eduard-Aexandru, Bonsang-Kitzis, Hélène, Brucker, Cosima, Cárdenas, Laura, Casajuana, Andrea, Cavalle, Pere, Cea, Jorge, Chiofalo, Benito, Cordeiro, Gloria, Coronado, Pluvio, Cuadra, Maria, Díez, Javier, Costa, Teresa Diniz da, Domingo, Santiago, Dostalek, Lukas, Elif, Fuat, Erasun, Diego, Fehr, Mathias, Fernandez-Gonzalez, Sergi, Ferrero, Annamaria, Fidalgo, Soledad, Fiol, Gabriel, Galaal, Khadra, García, José, Gebauer, Gerhard, Ghezzi, Fabio, Gilabert, Juan, Gomes, Nana, Gonçalves, Elisabete, Gonzalez, Virginia, Grandjean, Frederic, Guijarro, Miriam, Guyon, Frédéric, Haesen, Jolien, Hernandez-Cortes, Gines, Herrero, Sofía, Pete, Imre, Kalogiannidis, Ioannis, Karaman, Erbil, Kavallaris, Andreas, Klasa, Lukasz, Kotsopoulos, Ioannis, Kovachev, Stefan, Leht, Uppin Arno, Lekuona, Arantxa, Luyckx, Mathieu, Mallmann, Michael, Mancebo, Gemma, Mandic, Aljosa, Marina, Tiermes, Martin, Victor, Martín-Salamanca, María Belén, Lago, Víctor, Martinez, Alejandra, Meili, Gesine, Mendinhos, Gustavo, Mereu, Liliana, Mitrovic, Milena, Morales, Sara, Moratalla, Enrique, Gómez-Hidalgo, Natalia R, Morillas, Bibiana, Myriokefalitaki, Eva, PakižImre, Maja, Petousis, Stamatios, Pirtea, Laurentiu, Povolotskaya, Natalia, Prader, Sonia, Quesada, Alfonso, Redecha, Mikuláš, Roldan, Fernando, Rolland, Philip, Saaron, Reeli, Sarac, Cosmin-Paul, Scharf, Jens-Peter, Smrkolj, Špela, Sousa, Rita, Stepanyan, Artem, Študent, Vladimír, Tauste, Carmen, Trum, Hans, Turan, Taner, Undurraga, Manuela, Vázquez, Alicia, Vergote, Ignace, Vorgias, George, and Zapardiel, Ignacio

Published
2022
Full Text
View/download PDF

5. Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee

Author

Kurtz, Jean-Emmanuel, Gebski, Val, Sukhin, Vladyslav, Carey, Mark, Kong, Iwa, Glasspool, Rosalind M., Berek, Jonathan S., de Paiva Batista, Mariana, Hall, Marcia, Kim, Jae-Weon, Yeoshoua, Effi, Fujiwara, Noriko, Nam, Byung-Ho, Polleis, Sandra, Lee, Jung-Yun, Strojna, Aleksandra, Farrelly, Laura, Schwameis, Richard, Fossati, Roldano, Darlington, Anne-Sophie, Lai, Chyong-Huey, Wright, Alexi A., Rosenblat, Orgad, Harter, Phillip, Roxburgh, Patricia, Chowdhury, Rahul Roy, Chang, Ting-Chang, Paoletti, Xavier, and Friedlander, Michael

Published
2021
Full Text
View/download PDF

6. Assessment of palliative care training in gynaecological oncology: a survey among European Network of Young Gynae-Oncologists (ENYGO) members

Author

La Russa, Mariaclelia, Zapardiel, Ignacio, Zalewski, Kamil, Laky, Rene, Dursun, Polat, Sukhin, Vladyslav, Lindquist, David, and Lindemann, Kristina

Abstract

IntroductionPalliative care is an important aspect of gynaecological oncology practice. In order to successfully integrate end-of-life (EOL) care in the disease trajectory, it is crucial to incorporate systematic training in subspecialty programmes in gynaecological oncology. We aimed to evaluate the quality of training in palliative care across gynaecological oncology fellows in Europe and to provide a framework to facilitate learning opportunities.MethodsA web-based questionnaire was sent to members of the European Network of Young Gynae-Oncologists (ENYGO). The survey consisted of 36 items covering six domains: respondents’ characteristics, quality and quantity of teaching, curriculum achievements, observation and feedback, EOL clinical practice and attitudes about palliative care.ResultsOf the 703 clinicians enrolled in the study, 142 responded (20.2%). Although the majority worked in university hospitals, only half of them (47%) were in a formal subspecialty programme. The majority of respondents (60%) were trained without a mandatory rotation in palliative care units and considered the quality of EOL care teaching as ‘very poor’ or ‘poor’ (57.7%). The majority of respondents (71.6%) did not receive any supervision or feedback at the time of their first consultation on changing the goals of care.ConclusionOur study underlines lack of structured teaching and supervision in palliative care contents among European fellows in gynaecological oncology. Broad education of healthcare providers is a key factor to achieve the integration of palliative care in gynaecological oncology practice. Stakeholders like European Society of Gynaecological Oncology/ENYGO play an important role to facilitate educational activities and training programmes targeting to EOL care.

Published
2025
Full Text
View/download PDF

7. Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).

Author

Auranen, Annika, Powell, Matthew A., Sukhin, Vladyslav, Landrum, Lisa M., Ronzino, Graziana, Buscema, Joseph, Bauerschlag, Dirk, Lalisang, Roy, Bender, David, Gilbert, Lucy, Armstrong, Amy, Safra, Tamar, Nevadunsky, Nicole, Sebastianelli, Alexandra, Slomovitz, Brian, Ring, Kari, Coleman, Robert, Podzielinski, Iwona, Stuckey, Ashley, and Teneriello, Michael

Abstract

Background: In Part 1 of the phase III RUBY trial (NCT03981796) in patients with primary advanced or recurrent endometrial cancer (EC), dostarlimab plus carboplatin–paclitaxel (CP) significantly improved progression-free survival and overall survival compared with CP alone. Limited safety data have been reported for the combination of immunotherapies plus chemotherapy in this setting. Objectives: The objective of this analysis was to identify the occurrence of treatment-related adverse events (TRAEs) and immune-related adverse events (irAEs) and to describe irAE management in Part 1 of the RUBY trial. Design: RUBY is a phase III, randomized, double-blind, multicenter study of dostarlimab plus CP compared with CP alone in patients with primary advanced or recurrent EC. Methods: Patients were randomized 1:1 to dostarlimab 500 mg, or placebo, plus CP every 3 weeks for 6 cycles, followed by dostarlimab 1000 mg, or placebo, every 6 weeks for up to 3 years. Adverse events (AEs) were assessed according to Common Terminology Criteria for Adverse Events, version 4.03. Results: The safety population included 487 patients who received ⩾1 dose of treatment (241 dostarlimab plus CP; 246 placebo plus CP). Treatment-emergent AEs were experienced by 100% of patients in both arms. TRAEs occurred in 97.9% of the dostarlimab arm and 98.8% of the placebo arm. The most common TRAEs occurred at similar rates between arms and were mostly low grade. IrAEs occurred in 58.5% of patients in the dostarlimab arm and 37.0% of patients in the placebo arm. Dostarlimab- or placebo-related irAEs were reported in 40.7% of patients in the dostarlimab arm and 16.3% of the placebo arm. Conclusion: The safety profile of dostarlimab plus CP was generally consistent with that of the individual components. Dostarlimab plus CP has a favorable benefit–risk profile and is a new standard of care for patients with primary advanced or recurrent EC. Trial registration: NCT03981796. Plain language summary: Safety of dostarlimab plus carboplatin-paclitaxel compared with carboplatin-paclitaxel in primary advanced or recurrent endometrial cancer For many years, patients with primary advanced or recurrent endometrial cancer were treated with chemotherapy, specifically with a combination of carboplatin and paclitaxel. Recently, new treatments called immune checkpoint inhibitors have been used to treat endometrial cancer. Dostarlimab, an immune checkpoint inhibitor, is being tested to treat many types of cancer, including endometrial cancer. In the RUBY trial, a combination of dostarlimab plus chemotherapy was compared with chemotherapy alone as treatment for primary advanced or recurrent endometrial cancer. Results showed that patients treated with dostarlimab plus chemotherapy had a lower risk of their cancer becoming worse and a lower risk of dying. Results in this article describe the safety of dostarlimab plus chemotherapy compared with chemotherapy alone. All patients in the RUBY trial experienced at least one adverse event (an undesired effect that happens while receiving treatment or shortly after stopping treatment); most were determined to be caused by the cancer treatments. No differences in the frequency of the overall cancer treatment-related adverse events were seen in patients who received dostarlimab plus chemotherapy compared with those patients who received chemotherapy alone. Some patients experienced an immune-related adverse event. These are a specific type of undesired effect that can occur when patients are treated with immune checkpoint inhibitors. Immune-related adverse events occurred more frequently in patients who received dostarlimab plus chemotherapy than in those who received chemotherapy alone. Physicians were generally able to treat the immune-related adverse events, and only a low percentage of patients discontinued treatment because they experienced an immune-related adverse event. The types of adverse events seen were similar to a combination of those seen in patients who received dostarlimab alone or patients who received chemotherapy alone as treatment for endometrial cancer. Dostarlimab plus chemotherapy is a new standard of care for patients with primary advanced or recurrent endometrial cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Patient-reported outcomes (PROs) in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab (D) plus carboplatin/paclitaxel (CP) compared with CP in the ENGOT-EN6/GOG3031/RUBY trial.

Author

Mirza, Mansoor Raza, primary, Shahin, Mark S., additional, Powell, Matthew A., additional, Lundgren, Caroline, additional, Sukhin, Vladyslav, additional, Pothuri, Bhavana, additional, Gilbert, Lucy, additional, Gill, Sarah, additional, Ronzino, Graziana, additional, Nevadunsky, Nicole Suzanne, additional, Kommoss, Stefan, additional, Willmott, Lyndsay, additional, Boere, Ingrid, additional, Mathews, Cara Amanda, additional, Buscema, Joseph, additional, Teneriello, Michael, additional, Meyers, Oren, additional, Garside, Jamie, additional, Coleman, Robert L., additional, and Slomovitz, Brian M., additional

Published
2023
Full Text
View/download PDF

9. Radical hysterectomy in early cervical cancer in Europe: characteristics, outcomes and evaluation of ESGO quality indicators

Author

Boria, Felix, Chiva, Luis, Zanagnolo, Vanna, Querleu, Denis, Martin-Calvo, Nerea, Căpîlna, Mihai Emil, Fagotti, Anna, Kucukmetin, Ali, Mom, Constantijne, Chakalova, Galina, Shamistan, Aliyev, Malzoni, Mario, Narducci, Fabrice, Arencibia, Octavio, Raspagliesi, Francesco, Toptas, Tayfun, Cibula, David, Kaidarova, Dilyara, Meydanli, Mehmet Mutlu, Tavares, Mariana, Golub, Dmytro, Perrone, Anna Myriam, Poka, Robert, Tsolakidis, Dimitrios, Vujić, Goran, Jedryka, Marcin A, Zusterzeel, Petra L M, Beltman, Jogchum Jan, Goffin, Frederic, Haidopoulos, Dimitrios, Haller, Herman, Jach, Robert, Yezhova, Iryna, Berlev, Igor, Bernardino, Margarida, Bharathan, Rasiah, Lanner, Maximilian, Maenpaa, Minna M, Sukhin, Vladyslav, Feron, Jean-Guillaume, Fruscio, Robert, Kukk, Kersti, Ponce, Jordi, Alonso-Espías, María, Minguez, Jose Angel, Vázquez-Vicente, Daniel, Manzour, Nabil, Jurado, Matias, Castellanos, Teresa, Chacon, Enrique, and Alcazar, Juan Luis

Published
2021
Full Text
View/download PDF

10. #540 Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

Author

Auranen, Annika, primary, Black, Destin, additional, Sukhin, Vladyslav, additional, Sharma, Sudarshan, additional, Ronzino, Graziana, additional, Landrum, Lisa M, additional, Bauerschlag, Dirk, additional, Willmott, Lyndsay, additional, Lalisang, Roy, additional, Buscema, Joseph, additional, Gilbert, Lucy, additional, Coleman, Robert L, additional, Bender, David, additional, Armstrong, Amy, additional, Nevadunsky, Nicole, additional, Powell, Matthew A, additional, Dabrowski, Christine, additional, Stevens, Shadi, additional, Mirza, Mansoor Raza, additional, and Fleming, Evelyn, additional

Published
2023
Full Text
View/download PDF

11. SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer

Author

Chiva, Luis, Zanagnolo, Vanna, Querleu, Denis, Martin-Calvo, Nerea, Arévalo-Serrano, Juan, Căpîlna, Mihai Emil, Fagotti, Anna, Kucukmetin, Ali, Mom, Constantijne, Chakalova, Galina, Aliyev, Shamistan, Malzoni, Mario, Narducci, Fabrice, Arencibia, Octavio, Raspagliesi, Francesco, Toptas, Tayfun, Cibula, David, Kaidarova, Dilyara, Meydanli, Mehmet Mutlu, Tavares, Mariana, Golub, Dmytro, Perrone, Anna Myriam, Poka, Robert, Tsolakidis, Dimitrios, Vujić, Goran, Jedryka, Marcin A, Zusterzeel, Petra L M, Beltman, Jogchum Jan, Goffin, Frederic, Haidopoulos, Dimitrios, Haller, Herman, Jach, Robert, Yezhova, Iryna, Berlev, Igor, Bernardino, Margarida, Bharathan, Rasiah, Lanner, Maximilian, Maenpaa, Minna M, Sukhin, Vladyslav, Feron, Jean-Guillaume, Fruscio, Robert, Kukk, Kersti, Ponce, Jordi, Minguez, Jose Angel, Vázquez-Vicente, Daniel, Castellanos, Teresa, Chacon, Enrique, and Alcazar, Juan Luis

Published
2020
Full Text
View/download PDF

12. SATEN III—Splitting Adjuvant Treatment of stage III ENdometrial cancers: an international, multicenter study

Author

Kahramanoglu, Ilker, Meydanli, Mehmet Mutlu, Taranenka, Siarhei, Ayhan, Ali, Salman, Coskun, Sanci, Muzaffer, Demirkiran, Fuat, Ortac, Firat, Haidopoulos, Dimitrios, Sukhin, Vladyslav, Kaidarova, Dilyara, Stepanyan, Artem, Farazaneh, Farah, Aliyev, Shamistan, Ulrikh, Elena, Kurdiani, Dina, Yalcin, İbrahim, Mavrichev, Siarhei, Akilli, Huseyin, Sarı, Mustafa Erkan, Pletnev, Andrei, Aslan, Koray, Bese, Tugan, Kairbayev, Murat, Vlachos, Dimitrios, and Gultekin, Murat

Published
2019
Full Text
View/download PDF

13. SUCCOR quality: validation of ESGO quality indicators for surgical treatment of cervical cancer

Author

Boria, Felix, primary, Chiva, Luis, additional, Chacon, Enrique, additional, Zanagnolo, Vanna, additional, Fagotti, Anna, additional, Kucukmetin, Ali, additional, Mom, Constantijne, additional, Chakalova,, Galina, additional, Shamistan, Aliyev, additional, Malzoni, Mario, additional, Narducci, Fabrice, additional, Arencibia, Octavio, additional, Raspagliesi, Francesco, additional, Toptas, Tayfun, additional, Cibula, David, additional, Kaidarova, Dilyara, additional, Meydanli, Mehmet Mutlu, additional, Tavares, Mariana, additional, Golub, Dmytro, additional, Perrone, Anna Myriam, additional, Poka, Robert, additional, Zusterzeel, Petra L M, additional, Aluloski, Igor, additional, Goffin, Frederic, additional, Haidopoulos, Dimitrios, additional, Haller, Herman, additional, Jach, Robert, additional, Yezhova, Iryna, additional, Bernardino, Margarida, additional, Bharathan, Rasiah, additional, Maenpaa, Minna M, additional, Sukhin, Vladyslav, additional, Feron, Jean-Guillaume, additional, Fruscio, Robert, additional, Kukk, Kersti, additional, Ponce, Jordi, additional, Demirkiran, Fuat, additional, Vorgias, George, additional, Povolotskaya, Natalia, additional, Coronado Martín, Pluvio J, additional, Marina, Tiermes, additional, Zapardiel, Ignacio, additional, Bizzarri, Nicolò, additional, Gorostidi, Mikel, additional, Gutierrez, Monica, additional, Manzour, Nabil, additional, Berasaluce, Arantxa, additional, and Martin-Calvo, Nerea, additional

Published
2022
Full Text
View/download PDF

14. SUCCOR cone study: conization before radical hysterectomy

Author

Chacon, E, Manzour, N, Zanagnolo, V, Querleu, D, Núñez-Córdoba, J, Martin-Calvo, N, Căpîlna, M, Fagotti, A, Kucukmetin, A, Mom, C, Chakalova, G, Shamistan, A, Gil Moreno, A, Malzoni, M, Narducci, F, Arencibia, O, Raspagliesi, F, Toptas, T, Cibula, D, Kaidarova, D, Meydanli, M, Tavares, M, Golub, D, Perrone, A, Poka, R, Tsolakidis, D, Vujić, G, Jedryka, M, Zusterzeel, P, Beltman, J, Goffin, F, Haidopoulos, D, Haller, H, Jach, R, Yezhova, I, Berlev, I, Bernardino, M, Bharathan, R, Lanner, M, Maenpaa, M, Sukhin, V, Feron, J, Fruscio, R, Kukk, K, Ponce, J, Minguez, J, Vázquez-Vicente, D, Castellanos, T, Boria, F, Alcazar, J, Chiva, L, Chacon, Enrique, Manzour, Nabil, Zanagnolo, Vanna, Querleu, Denis, Núñez-Córdoba, Jorge M, Martin-Calvo, Nerea, Căpîlna, Mihai Emil, Fagotti, Anna, Kucukmetin, Ali, Mom, Constantijne, Chakalova, Galina, Shamistan, Aliyev, Gil Moreno, Antonio, Malzoni, Mario, Narducci, Fabrice, Arencibia, Octavio, Raspagliesi, Francesco, Toptas, Tayfun, Cibula, David, Kaidarova, Dilyara, Meydanli, Mehmet Mutlu, Tavares, Mariana, Golub, Dmytro, Perrone, Anna Myriam, Poka, Robert, Tsolakidis, Dimitrios, Vujić, Goran, Jedryka, Marcin A, Zusterzeel, Petra L M, Beltman, Jogchum Jan, Goffin, Frederic, Haidopoulos, Dimitrios, Haller, Herman, Jach, Robert, Yezhova, Iryna, Berlev, Igor, Bernardino, Margarida, Bharathan, Rasiah, Lanner, Maximilian, Maenpaa, Minna M, Sukhin, Vladyslav, Feron, Jean-Guillaume, Fruscio, Robert, Kukk, Kersti, Ponce, Jordi, Minguez, Jose Angel, Vázquez-Vicente, Daniel, Castellanos, Teresa, Boria, Felix, Alcazar, Juan Luis, Chiva, Luis, Chacon, E, Manzour, N, Zanagnolo, V, Querleu, D, Núñez-Córdoba, J, Martin-Calvo, N, Căpîlna, M, Fagotti, A, Kucukmetin, A, Mom, C, Chakalova, G, Shamistan, A, Gil Moreno, A, Malzoni, M, Narducci, F, Arencibia, O, Raspagliesi, F, Toptas, T, Cibula, D, Kaidarova, D, Meydanli, M, Tavares, M, Golub, D, Perrone, A, Poka, R, Tsolakidis, D, Vujić, G, Jedryka, M, Zusterzeel, P, Beltman, J, Goffin, F, Haidopoulos, D, Haller, H, Jach, R, Yezhova, I, Berlev, I, Bernardino, M, Bharathan, R, Lanner, M, Maenpaa, M, Sukhin, V, Feron, J, Fruscio, R, Kukk, K, Ponce, J, Minguez, J, Vázquez-Vicente, D, Castellanos, T, Boria, F, Alcazar, J, Chiva, L, Chacon, Enrique, Manzour, Nabil, Zanagnolo, Vanna, Querleu, Denis, Núñez-Córdoba, Jorge M, Martin-Calvo, Nerea, Căpîlna, Mihai Emil, Fagotti, Anna, Kucukmetin, Ali, Mom, Constantijne, Chakalova, Galina, Shamistan, Aliyev, Gil Moreno, Antonio, Malzoni, Mario, Narducci, Fabrice, Arencibia, Octavio, Raspagliesi, Francesco, Toptas, Tayfun, Cibula, David, Kaidarova, Dilyara, Meydanli, Mehmet Mutlu, Tavares, Mariana, Golub, Dmytro, Perrone, Anna Myriam, Poka, Robert, Tsolakidis, Dimitrios, Vujić, Goran, Jedryka, Marcin A, Zusterzeel, Petra L M, Beltman, Jogchum Jan, Goffin, Frederic, Haidopoulos, Dimitrios, Haller, Herman, Jach, Robert, Yezhova, Iryna, Berlev, Igor, Bernardino, Margarida, Bharathan, Rasiah, Lanner, Maximilian, Maenpaa, Minna M, Sukhin, Vladyslav, Feron, Jean-Guillaume, Fruscio, Robert, Kukk, Kersti, Ponce, Jordi, Minguez, Jose Angel, Vázquez-Vicente, Daniel, Castellanos, Teresa, Boria, Felix, Alcazar, Juan Luis, and Chiva, Luis

Abstract

OBJECTIVE: To evaluate disease-free survival of cervical conization prior to radical hysterectomy in patients with stage IB1 cervical cancer (International Federation of Gynecology and Obstetrics (FIGO) 2009). METHODS: A multicenter retrospective observational cohort study was conducted including patients from the Surgery in Cervical Cancer Comparing Different Surgical Aproaches in Stage IB1 Cervical Cancer (SUCCOR) database with FIGO 2009 IB1 cervical carcinoma treated with radical hysterectomy between January 1, 2013, and December 31, 2014. We used propensity score matching to minimize the potential allocation biases arising from the retrospective design. Patients who underwent conization but were similar for other measured characteristics were matched 1:1 to patients from the non-cone group using a caliper width ≤0.2 standard deviations of the logit odds of the estimated propensity score. RESULTS: We obtained a weighted cohort of 374 patients (187 patients with prior conization and 187 non-conization patients). We found a 65% reduction in the risk of relapse for patients who had cervical conization prior to radical hysterectomy (hazard ratio (HR) 0.35, 95% confidence interval (CI) 0.16 to 0.75, p=0.007) and a 75% reduction in the risk of death for the same sample (HR 0.25, 95% CI 0.07 to 0.90, p=0.033). In addition, patients who underwent minimally invasive surgery without prior conization had a 5.63 times higher chance of relapse compared with those who had an open approach and previous conization (HR 5.63, 95% CI 1.64 to 19.3, p=0.006). Patients who underwent minimally invasive surgery with prior conization and those who underwent open surgery without prior conization showed no differences in relapse rates compared with those who underwent open surgery with prior cone biopsy (reference) (HR 1.94, 95% CI 0.49 to 7.76, p=0.349 and HR 2.94, 95% CI 0.80 to 10.86, p=0.106 respectively). CONCLUSIONS: In this retrospective study, patients undergoing cervical conizatio

Published
2022

15. SUCCOR cone study: conization before radical hysterectomy

Author

Chacon, Enrique Manzour, Nabil Zanagnolo, Vanna Querleu, Denis Nunez-Cordoba, Jorge M. Martin-Calvo, Nerea Capilna, Mihai Emil Fagotti, Anna Kucukmetin, Ali Mom, Constantijne and Chakalova, Galina Shamistan, Aliyev Gil Moreno, Antonio and Malzoni, Mario Narducci, Fabrice Arencibia, Octavio and Raspagliesi, Francesco Toptas, Tayfun Cibula, David and Kaidarova, Dilyara Meydanli, Mehmet Mutlu Tavares, Mariana and Golub, Dmytro Perrone, Anna Myriam Poka, Robert Tsolakidis, Dimitrios Vujic, Goran Jedryka, Marcin A. Zusterzeel, Petra L. M. Beltman, Jogchum Jan Goffin, Frederic Haidopoulos, Dimitrios Haller, Herman Jach, Robert Yezhova, Iryna and Berlev, Igor Bernardino, Margarida Bharathan, Rasiah Lanner, Maximilian Maenpaa, Minna M. Sukhin, Vladyslav Feron, Jean-Guillaume Fruscio, Robert Kukk, Kersti Ponce, Jordi and Angel Minguez, Jose Vazquez-Vicente, Daniel Castellanos, Teresa and Boria, Felix Luis Alcazar, Juan Chiva, Luis SUCCOR Study Grp

Abstract

Objective To evaluate disease-free survival of cervical conization prior to radical hysterectomy in patients with stage IB1 cervical cancer (International Federation of Gynecology and Obstetrics (FIGO) 2009). Methods A multicenter retrospective observational cohort study was conducted including patients from the Surgery in Cervical Cancer Comparing Different Surgical Aproaches in Stage IB1 Cervical Cancer (SUCCOR) database with FIGO 2009 IB1 cervical carcinoma treated with radical hysterectomy between January 1, 2013, and December 31, 2014. We used propensity score matching to minimize the potential allocation biases arising from the retrospective design. Patients who underwent conization but were similar for other measured characteristics were matched 1:1 to patients from the non-cone group using a caliper width

Published
2022

16. Patient-reported outcomes from the phase III, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 Study of pembrolizumab plus concurrent chemoradiotherapy among patients with high-risk, locally advanced cervical cancer.

Author

Randall, Leslie, Sukhin, Vladyslav, Colombo, Nicoletta, Korach, Jacob, Matsumoto, Takashi, Lalondrelle, Susan, Vizkeleti, Julia, Samouelian, Vanessa, Salani, Ritu, Salman, Pamela, Nogueira-Rodrigues, Angelica, Ayhan, Ali, Frentzas, Sophia, Cueva, Juan, Kim, Yong-Man, Petru, Edgar, Milla, Dency Pilar, Sehouli, Jalid, Saevets, Valeriya, and Yamada, Karin

Subjects
*PATIENT reported outcome measures, *CERVICAL cancer, *CHEMORADIOTHERAPY, *PEMBROLIZUMAB
Published
2024
Full Text
View/download PDF

17. Radical hysterectomy in early cervical cancer in Europe: characteristics, outcomes and evaluation of ESGO quality indicators

Author

Boria, Felix Chiva, Luis Zanagnolo, Vanna Querleu, Denis and Martin-Calvo, Nerea Capilna, Mihai Emil Fagotti, Anna and Kucukmetin, Ali Mom, Constantijne Chakalova, Galina and Shamistan, Aliyev Malzoni, Mario Narducci, Fabrice and Arencibia, Octavio Raspagliesi, Francesco Toptas, Tayfun and Cibula, David Kaidarova, Dilyara Meydanli, Mehmet Mutlu and Tavares, Mariana Golub, Dmytro Perrone, Anna Myriam Poka, Robert Tsolakidis, Dimitrios Vujic, Goran Jedryka, Marcin A. and Zusterzeel, Petra L. M. Beltman, Jogchum Jan Goffin, Frederic Haidopoulos, Dimitrios Haller, Herman Jach, Robert and Yezhova, Iryna Berlev, Igor Bernardino, Margarida and Bharathan, Rasiah Lanner, Maximilian Maenpaa, Minna M. and Sukhin, Vladyslav Feron, Jean-Guillaume Fruscio, Robert and Kukk, Kersti Ponce, Jordi Alonso-Espias, Maria Angel Minguez, Jose Vazquez-Vicente, Daniel Manzour, Nabil Jurado, Matias Castellanos, Teresa Chacon, Enrique Luis Alcazar, Juan

Abstract

Introduction Comprehensive updated information on cervical cancer surgical treatment in Europe is scarce. Objective To evaluate baseline characteristics of women with early cervical cancer and to analyze the outcomes of the ESGO quality indicators after radical hysterectomy in the SUCCOR database. Methods The SUCCOR database consisted of 1272 patients who underwent radical hysterectomy for stage IB1 cervical cancer (FIGO 2009) between January 2013 and December 2014. After exclusion criteria, the final sample included 1156 patients. This study first described the clinical, surgical, pathological, and follow-up variables of this population and then analyzed the outcomes (disease-free survival and overall survival) after radical hysterectomy. Surgical-related ESGO quality indicators were assessed and the accomplishment of the stated recommendations was verified. Results The mean age of the patients was 47.1 years (SD 10.8), with a mean body mass index of 25.4 kg/m(2) (SD 4.9). A total of 423 (36.6%) patients had a previous cone biopsy. Tumor size (clinical examination)

Published
2021

19. Subspecialty training in Europe: a report by the European Network of Young Gynaecological Oncologists

Author

Lanner, Maximilian, primary, Nikolova, Tanja, additional, Gutic, Bojana, additional, Nikolova, Natasha, additional, Pletnev, Andrei, additional, Selcuk, Ilker, additional, Vlachos, Dimitrios-Efthymios, additional, Razumova, Zoia, additional, Bizzarri, Nicolò, additional, Theofanakis, Charlampos, additional, Lepka, Piotr, additional, Kahramanoglu, Ilker, additional, Han, Sileny, additional, Nasser, Sara, additional, Molnar, Szabolcs, additional, Hudry, Delphine, additional, Montero-Macías, Rosa, additional, de Lange, Natascha, additional, Macuks, Ronalds, additional, Hasanov, Mir Fuad, additional, Karimbayli, Ramina, additional, Gagua, Irina, additional, Andrade, Claudia, additional, Pardal, Catarina, additional, Dotlic, Jelena, additional, Alvarez, Rosa Maria, additional, Hruda, Martin, additional, Fruhauf, Filip, additional, Ekdahl, Linnea, additional, Antonsen, Sofie Leisby, additional, Sukhin, Vladyslav, additional, Eriksson, Ane Gerda Zahl, additional, Gliozheni, Elko, additional, Delic, Ratko, additional, Satanova, Alima, additional, Kovacevic, Nina, additional, Gristsenko, Liidia, additional, Babloyan, Suzanna, additional, Zalewski, Kamil, additional, and Bharathan, Rasiah, additional

Published
2020
Full Text
View/download PDF

21. Assessment of palliative care training in gynaecological oncology : a survey among European Network of Young Gynae-Oncologists (ENYGO) members

Author

La Russa, Mariaclelia, Zapardiel, Ignacio, Zalewski, Kamil, Laky, Rene, Dursun, Polat, Sukhin, Vladyslav, Lindquist, David, Lindemann, Kristina, La Russa, Mariaclelia, Zapardiel, Ignacio, Zalewski, Kamil, Laky, Rene, Dursun, Polat, Sukhin, Vladyslav, Lindquist, David, and Lindemann, Kristina

Abstract

INTRODUCTION: Palliative care is an important aspect of gynaecological oncology practice. In order to successfully integrate end-of-life (EOL) care in the disease trajectory, it is crucial to incorporate systematic training in subspecialty programmes in gynaecological oncology. We aimed to evaluate the quality of training in palliative care across gynaecological oncology fellows in Europe and to provide a framework to facilitate learning opportunities. METHODS: A web-based questionnaire was sent to members of the European Network of Young Gynae-Oncologists (ENYGO). The survey consisted of 36 items covering six domains: respondents' characteristics, quality and quantity of teaching, curriculum achievements, observation and feedback, EOL clinical practice and attitudes about palliative care. RESULTS: Of the 703 clinicians enrolled in the study, 142 responded (20.2%). Although the majority worked in university hospitals, only half of them (47%) were in a formal subspecialty programme. The majority of respondents (60%) were trained without a mandatory rotation in palliative care units and considered the quality of EOL care teaching as 'very poor' or 'poor' (57.7%). The majority of respondents (71.6%) did not receive any supervision or feedback at the time of their first consultation on changing the goals of care. CONCLUSION: Our study underlines lack of structured teaching and supervision in palliative care contents among European fellows in gynaecological oncology. Broad education of healthcare providers is a key factor to achieve the integration of palliative care in gynaecological oncology practice. Stakeholders like European Society of Gynaecological Oncology/ENYGO play an important role to facilitate educational activities and training programmes targeting to EOL care.

Published
2020
Full Text
View/download PDF

22. SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer

Author

Chiva, L, Zanagnolo, V, Querleu, D, Martin-Calvo, N, Arévalo-Serrano, J, Căpîlna, M, Fagotti, A, Kucukmetin, A, Mom, C, Chakalova, G, Aliyev, S, Malzoni, M, Narducci, F, Arencibia, O, Raspagliesi, F, Toptas, T, Cibula, D, Kaidarova, D, Meydanli, M, Tavares, M, Golub, D, Perrone, A, Poka, R, Tsolakidis, D, Vujić, G, Jedryka, M, Zusterzeel, P, Beltman, J, Goffin, F, Haidopoulos, D, Haller, H, Jach, R, Yezhova, I, Berlev, I, Bernardino, M, Bharathan, R, Lanner, M, Maenpaa, M, Sukhin, V, Feron, J, Fruscio, R, Kukk, K, Ponce, J, Minguez, J, Vázquez-Vicente, D, Castellanos, T, Chacon, E, Alcazar, J, Chiva, Luis, Zanagnolo, Vanna, Querleu, Denis, Martin-Calvo, Nerea, Arévalo-Serrano, Juan, Căpîlna, Mihai Emil, Fagotti, Anna, Kucukmetin, Ali, Mom, Constantijne, Chakalova, Galina, Aliyev, Shamistan, Malzoni, Mario, Narducci, Fabrice, Arencibia, Octavio, Raspagliesi, Francesco, Toptas, Tayfun, Cibula, David, Kaidarova, Dilyara, Meydanli, Mehmet Mutlu, Tavares, Mariana, Golub, Dmytro, Perrone, Anna Myriam, Poka, Robert, Tsolakidis, Dimitrios, Vujić, Goran, Jedryka, Marcin A, Zusterzeel, Petra L M, Beltman, Jogchum Jan, Goffin, Frederic, Haidopoulos, Dimitrios, Haller, Herman, Jach, Robert, Yezhova, Iryna, Berlev, Igor, Bernardino, Margarida, Bharathan, Rasiah, Lanner, Maximilian, Maenpaa, Minna M, Sukhin, Vladyslav, Feron, Jean-Guillaume, Fruscio, Robert, Kukk, Kersti, Ponce, Jordi, Minguez, Jose Angel, Vázquez-Vicente, Daniel, Castellanos, Teresa, Chacon, Enrique, Alcazar, Juan Luis, Chiva, L, Zanagnolo, V, Querleu, D, Martin-Calvo, N, Arévalo-Serrano, J, Căpîlna, M, Fagotti, A, Kucukmetin, A, Mom, C, Chakalova, G, Aliyev, S, Malzoni, M, Narducci, F, Arencibia, O, Raspagliesi, F, Toptas, T, Cibula, D, Kaidarova, D, Meydanli, M, Tavares, M, Golub, D, Perrone, A, Poka, R, Tsolakidis, D, Vujić, G, Jedryka, M, Zusterzeel, P, Beltman, J, Goffin, F, Haidopoulos, D, Haller, H, Jach, R, Yezhova, I, Berlev, I, Bernardino, M, Bharathan, R, Lanner, M, Maenpaa, M, Sukhin, V, Feron, J, Fruscio, R, Kukk, K, Ponce, J, Minguez, J, Vázquez-Vicente, D, Castellanos, T, Chacon, E, Alcazar, J, Chiva, Luis, Zanagnolo, Vanna, Querleu, Denis, Martin-Calvo, Nerea, Arévalo-Serrano, Juan, Căpîlna, Mihai Emil, Fagotti, Anna, Kucukmetin, Ali, Mom, Constantijne, Chakalova, Galina, Aliyev, Shamistan, Malzoni, Mario, Narducci, Fabrice, Arencibia, Octavio, Raspagliesi, Francesco, Toptas, Tayfun, Cibula, David, Kaidarova, Dilyara, Meydanli, Mehmet Mutlu, Tavares, Mariana, Golub, Dmytro, Perrone, Anna Myriam, Poka, Robert, Tsolakidis, Dimitrios, Vujić, Goran, Jedryka, Marcin A, Zusterzeel, Petra L M, Beltman, Jogchum Jan, Goffin, Frederic, Haidopoulos, Dimitrios, Haller, Herman, Jach, Robert, Yezhova, Iryna, Berlev, Igor, Bernardino, Margarida, Bharathan, Rasiah, Lanner, Maximilian, Maenpaa, Minna M, Sukhin, Vladyslav, Feron, Jean-Guillaume, Fruscio, Robert, Kukk, Kersti, Ponce, Jordi, Minguez, Jose Angel, Vázquez-Vicente, Daniel, Castellanos, Teresa, Chacon, Enrique, and Alcazar, Juan Luis

Abstract

Background: Minimally invasive surgery in cervical cancer has demonstrated in recent publications worse outcomes than open surgery. The primary objective of the SUCCOR study, a European, multicenter, retrospective, observational cohort study was to evaluate disease-free survival in patients with stage IB1 (FIGO 2009) cervical cancer undergoing open vs minimally invasive radical hysterectomy. As a secondary objective, we aimed to investigate the association between protective surgical maneuvers and the risk of relapse. Methods: We obtained data from 1272 patients that underwent a radical hysterectomy by open or minimally invasive surgery for stage IB1 cervical cancer (FIGO 2009) from January 2013 to December 2014. After applying all the inclusion-exclusion criteria, we used an inverse probability weighting to construct a weighted cohort of 693 patients to compare outcomes (minimally invasive surgery vs open). The first endpoint compared disease-free survival at 4.5 years in both groups. Secondary endpoints compared overall survival among groups and the impact of the use of a uterine manipulator and protective closure of the colpotomy over the tumor in the minimally invasive surgery group. Results: Mean age was 48.3 years (range; 23-83) while the mean BMI was 25.7 kg/m2 (range; 15-49). The risk of recurrence for patients who underwent minimally invasive surgery was twice as high as that in the open surgery group (HR, 2.07; 95% CI, 1.35 to 3.15; P=0.001). Similarly, the risk of death was 2.42-times higher than in the open surgery group (HR, 2.45; 95% CI, 1.30 to 4.60, P=0.005). Patients that underwent minimally invasive surgery using a uterine manipulator had a 2.76-times higher hazard of relapse (HR, 2.76; 95% CI, 1.75 to 4.33; P<0.001) and those without the use of a uterine manipulator had similar disease-free-survival to the open surgery group (HR, 1.58; 95% CI, 0.79 to 3.15; P=0.20). Moreover, patients that underwent minimally invasive surgery with protective va

Published
2020

23. Saten III- Splitting Adjuvant Treatment into subgroups of stage III endometrioid Endometrial cancers: An international, multicenter study

Author

Kahramanoglu, Ilker, primary, Mutlu Meydanli, Mehmet, primary, Taranenka, Siarhei, primary, Ayhan, Ali, primary, coskun salman, mehmet, primary, Sanci, Muzaffer, primary, Demirkiran, Fuat, primary, Ortac, Firat, primary, Haidopoulos, Dimitrios, primary, Sukhin, Vladyslav, primary, Kaidarova, Dilyara, primary, stepanyan, artem, primary, Farzaneh, Farah, primary, Shamistan, Shamistan, primary, Ulrikh, Elena, primary, Kurdiani, Dina, primary, Ibrahim, Yalcin, primary, Mavrichev, Siarhey, primary, Akilli, Huseyin, primary, Erkan Sari, Mustafa, primary, Pletnev, Andrei, primary, Aslan, Koray, primary, Kairbayev, Murat, primary, Vlachos, Dimitrios-Efthymios, primary, and Gültekin, Murat, primary

Published
2019
Full Text
View/download PDF

26. Patient-reported Outcomes in Patients With Primary Advanced or Recurrent Endometrial Cancer Who Received Dostarlimab Plus Carboplatin-Paclitaxel vs Carboplatin-Paclitaxel in the ENGOT-EN6/GOG3031/RUBY Trial.

Author

Mirza, Mansoor Raza, Powell, Matthew A., Lundgren, Caroline, Sukhin, Vladyslav, and Pothuri, Bhavana

Subjects
THERAPEUTIC use of monoclonal antibodies, THERAPEUTIC use of antineoplastic agents, CARBOPLATIN, HEALTH outcome assessment, CANCER relapse, CONFERENCES & conventions, CANCER patients, ENDOMETRIAL tumors, PACLITAXEL
Abstract

Background: RUBY (NCT03981796) is a phase 3, randomized, placebo-controlled trial in patients with primary advanced or recurrent endometrial cancer (pA/rEC). In RUBY, dostarlimab plus carboplatin-paclitaxel (D+CP) demonstrated clinically meaningful efficacy in patients with pA/rEC, including a significant improvement in progression-free survival (PFS), compared with placebo (PBO) plus carboplatin-paclitaxel (PBO+CP).1 Objective: To examine and report similarities and differences in patient-reported outcomes (PROs) in patients with pA/rEC who received either D+CP or PBO+CP in the phase 3 RUBY trial. Methods: A total of 494 patients with pA/rEC were randomized 1:1 to receive either D+CP or PBO+CP every 3 weeks for 6 cycles, followed by D or PBO alone every 6 weeks for up to 3 years or until disease progression. As a secondary endpoint, PRO questionnaires for patients with any cancer (ie, the European Organisation for Research and Treatment of Cancer [EORTC] QLQ-C30) and for patients with endometrial cancer (ie, EORTC QLQ-EN24) were administered on day 1 of each treatment cycle (C), at end of treatment, and at safety and survival follow-up points. Changes in patients' scores over time were calculated using mixed model for repeated measures analyses, and least-squares means (LSMs) were used to quantify the difference between treatment arms in change observed in patients' scores over time. Results are reported here for C7 (the end of chemotherapy) and C13 (the end of 1 year of study follow-up). Results: PRO scores were similar in patients who received D+CP and PBO+CP through the chemotherapy period (C7). After 1 year of study follow-up (C13), the mean change in global health status/quality-of-life (GHS/QoL) score from baseline was 3.3 (SD, 23.51) with D+CP, and -0.9 (SD, 19.25) with PBO+CP (positive score indicates improvement; ≥10-point change was considered clinically meaningful). Over the 3-year study period, no differences between the 2 treatment arms were detected (P≥.05 indicated no significant difference) based on LSMs; more specifically, GHS/QoL was 0.5 (P=.72), physical function was -0.7 (P=.63), fatigue was 0.2 (P=.91), and pain was -1.0 (P=.62). At the end of study treatment, patients who received D+CP reported improvement in back/pelvic pain compared with baseline; patients receiving PBO+CP reported worsening of GHS/QoL, social functioning, body image, and change in taste compared with baseline. Conclusions: In this study, patients with pA/rEC receiving D+CP experienced significantly improved PFS while maintaining health-related QoL. These findings further support the use of D+CP as a standard of care in treating patients with pA/rEC. Funding: This study was sponsored by GSK. Editorial support provided by ArticulateScience, LLC, and funded by GSK. [ABSTRACT FROM AUTHOR]

Published
2023

27. Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.

Author

Mirza, Mansoor Raza, Powell, Matthew A., Lundgren, Caroline, Sukhin, Vladyslav, Pothuri, Bhavana, Gilbert, Lucy, Gill, Sarah, Ronzino, Graziana, Nevadunsky, Nicole, Kommoss, Stefan, Willmott, Lyndsay, Boere, Ingrid, Mathews, Cara Amanda, Buscema, Joseph, Teneriello, Michael, Shahin, Mark S., Meyers, Oren, Garside, Jamie, Coleman, Robert L., and Slomovitz, Brian M.

Published
2023
Full Text
View/download PDF

28. Gynecologic Oncology Training Systems in Europe

Author

Gultekin, Murat, primary, Dursun, Polat, additional, Vranes, Boris, additional, Laky, Rene, additional, Bossart, Michaela, additional, Grabowski, Jacek P., additional, Piek, Jurgen M. J., additional, Manchanda, Ranjit, additional, Grimm, Christoph, additional, Dallaku, Kastriot, additional, Babloyan, Syuzanna, additional, Moisei, Anna, additional, Van Gorp, Toon, additional, Cadron, Isabelle, additional, Markov, Peter, additional, Micevska, Ana, additional, Halaska, Michael, additional, Steffensen, Karina Dahl, additional, Gristsenko, Liidia, additional, Nissi, Ritva, additional, Lambaudie, Eric, additional, Tsitsishvili, Zaza, additional, Haidopoulos, Dimitrios, additional, Tsolakidis, Dimitrios, additional, Novak, Zoltan, additional, Peiretti, Michele, additional, Dunenova, Gauhar, additional, Macuks, Ronalds, additional, Hetland, Thea E., additional, Michelsen, Trond M., additional, Martins, Filipe C., additional, Achimas-Cadariu, Patriciu, additional, Ulrikh, Elena A., additional, Uharcek, Peter, additional, Malic, Sladjana, additional, Ognjenovic, Dejan, additional, Zapardiel, Ignacio, additional, Johann, Silke, additional, and Sukhin, Vladyslav S., additional

Published
2011
Full Text
View/download PDF

29. Assessment of palliative care training in gynaecological oncology: a survey among European Network of Young Gynae-Oncologists (ENYGO) members.

Author

La Russa M, Zapardiel I, Zalewski K, Laky R, Dursun P, Sukhin V, Lindquist D, and Lindemann K

Subjects
Humans, Europe, Female, Gynecology education, Surveys and Questionnaires, Adult, Male, Genital Neoplasms, Female therapy, Terminal Care, Curriculum, Attitude of Health Personnel, Middle Aged, Palliative Care, Medical Oncology education
Abstract

Introduction: Palliative care is an important aspect of gynaecological oncology practice. In order to successfully integrate end-of-life (EOL) care in the disease trajectory, it is crucial to incorporate systematic training in subspecialty programmes in gynaecological oncology. We aimed to evaluate the quality of training in palliative care across gynaecological oncology fellows in Europe and to provide a framework to facilitate learning opportunities., Methods: A web-based questionnaire was sent to members of the European Network of Young Gynae-Oncologists (ENYGO). The survey consisted of 36 items covering six domains: respondents' characteristics, quality and quantity of teaching, curriculum achievements, observation and feedback, EOL clinical practice and attitudes about palliative care., Results: Of the 703 clinicians enrolled in the study, 142 responded (20.2%). Although the majority worked in university hospitals, only half of them (47%) were in a formal subspecialty programme. The majority of respondents (60%) were trained without a mandatory rotation in palliative care units and considered the quality of EOL care teaching as 'very poor' or 'poor' (57.7%). The majority of respondents (71.6%) did not receive any supervision or feedback at the time of their first consultation on changing the goals of care., Conclusion: Our study underlines lack of structured teaching and supervision in palliative care contents among European fellows in gynaecological oncology. Broad education of healthcare providers is a key factor to achieve the integration of palliative care in gynaecological oncology practice. Stakeholders like European Society of Gynaecological Oncology/ENYGO play an important role to facilitate educational activities and training programmes targeting to EOL care., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2025. No commercial re-use. See rights and permissions. Published by BMJ Group.)

Published
2024
Full Text
View/download PDF

30. Subspecialty training in Europe: a report by the European Network of Young Gynaecological Oncologists.

Author

Lanner M, Nikolova T, Gutic B, Nikolova N, Pletnev A, Selcuk I, Vlachos DE, Razumova Z, Bizzarri N, Theofanakis C, Lepka P, Kahramanoglu I, Han S, Nasser S, Molnar S, Hudry D, Montero-Macías R, de Lange N, Macuks R, Hasanov MF, Karimbayli R, Gagua I, Andrade C, Pardal C, Dotlic J, Alvarez RM, Hruda M, Fruhauf F, Ekdahl L, Antonsen SL, Sukhin V, Eriksson AGZ, Gliozheni E, Delic R, Satanova A, Kovacevic N, Gristsenko L, Babloyan S, Zalewski K, and Bharathan R

Subjects
Europe, Female, Humans, Gynecology education, Oncologists education
Abstract

Background: ESGO (European Society of Gynaecological Oncology) and partners are continually improving the developmental opportunities for gynaecological oncology fellows. The objectives of this survey were to evaluate the progress in the infrastructure of the training systems in Europe over the past decade. We also evaluated training and assessment techniques, the perceived relevance of ENYGO (European Network of Young Gynaecological Oncologists) initiatives, and unmet needs of trainees., Methodology: National representatives of ENYGO from 39 countries were contacted with an electronic survey. A graduation in well/moderately/loosely-structured training systems was performed. Descriptive statistical analysis and frequency tables, as well as two-sided Fisher's exact test, were used., Results: National representatives from 33 countries answered our survey questionnaire, yielding a response rate of 85%. A national fellowship is offered in 22 countries (66.7%). A logbook to document progress during training is mandatory in 24 (72.7%) countries. A logbook of experience is only utilized in a minority of nations (18%) for assessment purposes. In 42.4% of countries, objective assessments are recognized. Trainees in most countries (22 (66.7%)) requested additional training in advanced laparoscopic surgery. 13 (39.4%) countries have a loosely-structured training system, 11 (33.3%) a moderately-structured training system, and 9 (27.3%) a well-structured training system., Conclusion: Since the last publication in 2011, ENYGO was able to implement new activities, workshops, and online education to support training of gynaecological oncology fellows, which were all rated by the respondents as highly useful. This survey also reveals the limitations in establishing more accredited centers, centralized cancer care, and the lack of laparoscopic training., Competing Interests: Competing interests: None declared., (© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results